POZEN Announces Positive Top Line Results For Its PN 400 Phase 3 Trials
POZEN Inc. (NASDAQ: POZN), today announced positive Phase 3 trial results for its PN 400 product candidate (enteric coated naproxen 500 mg and immediate release esomeprazole 20 mg) conducted by POZEN under an agreed Special Protocol Assessment with the FDA. Both the PN 400-301/302 studies achieved the primary endpoints.
More: continued here
Filed under: Arthritis on December 6th, 2008